Processing methods for human amniotic membrane as scaffold for tissue engineering with mesenchymal stromal human cells

Echarte, L.; Grazioli, Guillermo; Pereira, Lívia da Costa; Francia, Alejandro; Pérez, Héctor; Kuzuian, W.; Vicentino, W.; Pardo, Helena; Mombrú, Álvaro W.; Maglia, Alvaro; Touriño, Cristina; Alvarez, I.

doi:10.1007/s10561-022-10014-8

Cited by 4 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs associated with decellularized hAM (DhAM) have been studied in several in vitro and in vivo models. In vitro studies showed that DhAM can be used to grow MSCs derived from human tissues as from dental pulp, iliac crest bone-marrow (Echarte et al 2022) human adipose tissue-derived stem cells (Gholipourmalekabadi et al 2016, Naasani et al 2019, Hadipour et al 2021, sclerocorneal limbus (Naasani et al 2018) and epithelial cells (Dragúňová et al 2019). The DhAM was combined with bone marrow MSCs to investigate the wound healing effects in full thickness skin defects in rabbits (Kim et al 2009).…”

Section: Introductionmentioning

confidence: 99%

Bioscaffold developed with decellularized human amniotic membrane seeded with mesenchymal stromal cells: assessment of efficacy and safety profiles in a second-degree burn preclinical model

Naasani¹,

Pretto²,

Zanatelli³

et al. 2022

Biofabrication

View full text Add to dashboard Cite

Therapies to deep burn injuries remain a global challenge. Human amniotic membrane (hAM) is a biomaterial that has been increasingly explored by the field of regenerative medicine. A decellularized hAM (DhAM) can be used as scaffold for mesenchymal stromal cells (MSCs) to grow without the loss of their stemness potential, allowing its application as cell therapy for wound healing. In this work, we associated DhAM with adipose-derived mesenchymal stromal cells (DhAM+AD-MSC), as a therapy strategy for second-degree burns in a preclinical model . Animals with induced second-degree burns were divided into 4 groups: control, which consists of a non-adherent gauze; a synthetic commercial dressing as the positive control (control+); DhAM; and DhAM plus rat AD-MSCs (DhAM+AD-MSCs), followed by detailed and long term analysis (5 weeks). The macroscopical analysis showed the healing improvement in the wound area after the DhAM+AD-MSC treatment. Histological analysis also showed no alteration in the animal organs and a regular epithelial progression in comparison to the control. This observation was also confirmed by the analysis of suprabasal layers in the neoepidermis with CK10, showing a stratified and differentiated epithelium, when compared to Control and Control+. A strong CD73 (ecto-5′-nucleotidase) labeling was observed in the first two weeks postburn in dermis and epidermis. The expression in dermis was stronger in the second week in the middle of the wound, when comparing the Control+ with DhAM+AD-MSCs (p=0.0238). In the epidermis the expression of CD73 was increased in all regions when compared to the control. This data suggests the involvement of this protein on wound healing. A low CD11b labeling was observed in DhAM+AD-MSCs treatment group mainly in the last treatment week, in comparison to Control and Control+ (p<0.0001), which indicates a reduction in the inflammatory process. MSCs through CD73 can release high concentrations of adenosine, an immunosuppressive molecule, suggesting that this could be the mechanism by which the inflammation was better modulated in the DhAM+AD-MSCs group. The results obtained with this preclinical model confirm the effectiveness and safety of this low-cost and highly available dressing for future clinical application as a therapy for burn treatments.

show abstract

Section: Introductionmentioning

confidence: 99%

Bioscaffold developed with decellularized human amniotic membrane seeded with mesenchymal stromal cells: assessment of efficacy and safety profiles in a second-degree burn preclinical model

Naasani¹,

Pretto²,

Zanatelli³

et al. 2022

Biofabrication

View full text Add to dashboard Cite

show abstract

“…Clinical studies have demonstrated that hAM can treat moderate and severe intrauterine adhesions with specic feasibility and safety benets, as the stem cells in hAM could effectively promote the repair of endometriosis. [6][7][8][9] Furthermore, treating intrauterine adhesions with hAM can restore the self-repairing ability of the endometrium and restore the normal menstrual and reproductive functions of women. [10][11][12][13][14] However, the mechanical properties, particularly the tensile property of the hAMs used in surgeries, are insufficient, severely restricting the promotion and application of hAMs.…”

Section: Introductionmentioning

confidence: 99%

Dramatic improvement in the mechanical properties of polydopamine/polyacrylamide hydrogel mediated human amniotic membrane

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Obtaining organs and tissues for transplantation from BD-DD is a widely accepted strategy; however, during the routine BD-DD process, procuring the BM is not performed. Therefore, the use of BM from BD-DD as an alternative source of allo-hMSC is promising but has been little explored ( 11 - 15 ). The aim of the present study was to evaluate the potential of femur BM (FBM) from BD-DD as a source of hMSC for cell therapy.…”

Section: Introductionmentioning

confidence: 99%

Femur bone marrow from brain death deceased donors as source of human mesenchymal stromal cells for cell therapy

Echarte¹,

Sujanov²,

Machin³

et al. 2023

Stem Cell Investig

View full text Add to dashboard Cite

Background The use of a deceased donor (DD) as an alternative source of human mesenchymal stromal cells (hMSC) is promising, but has been little explored. This study evaluated the potential of femur bone marrow (FBM) from brain-death donors as a source of hMSC and compared this with hMSC from matched iliac crest bone marrow (ICBM). Methods Sixteen donor-matched FBM and ICBM samples were processed from brain-death donors. We analyzed the starting material and compared cell yield, phenotypic profile and differentiation capacity of hMSC. Results Neither the amount of nucleated cells per gram (14.6×10 6 ±10.3×10 6 from FBM vs. 38.8×10 6 ±34.6×10 6 from ICBM, P≥0.09) nor the frequency of CFU-F (0.0042%±0.0036% in FBM vs. 0.0057%±0.0042% in ICBM, P≥0.73) differ significantly from FBM or ICBM. Cell cultures from both sources were obtained and hMSC yields showed that there were no significant differences in hMSC obtained per gram of bone marrow (BM) when comparing femur with iliac crest samples. At passage 2, 12.5×10 6 ±12.9×10 6 and 5.0×10 6 ±4.4×10 6 hMSC per gram of BM were obtained from FBM and ICBM, respectively. FBM and ICBM hMSC express CD73, CD90, CD105, but not hematopoietic lineage markers [CD45, CD34, CD11, CD19 and isotype of HLA clase II (HLA-DR)]. HLA-A expression from both sources was clearly detected, while HLA-B was weakly expressed or undetectable and HLA-DR was undetectable. Cells from both sources were differentiated in vitro into osteoblasts, adipocytes and chondroblasts. Conclusions To our knowledge, there are no previous studies evaluating BM from femur dead donors as a source of hMSC. Our findings confirm that it is feasible to expand cells from FBM from brain-death donors meeting in vitro characteristics of hMSC, making them a promising source for clinical translation.

show abstract

Processing methods for human amniotic membrane as scaffold for tissue engineering with mesenchymal stromal human cells

Cited by 4 publications

References 48 publications

Bioscaffold developed with decellularized human amniotic membrane seeded with mesenchymal stromal cells: assessment of efficacy and safety profiles in a second-degree burn preclinical model

Bioscaffold developed with decellularized human amniotic membrane seeded with mesenchymal stromal cells: assessment of efficacy and safety profiles in a second-degree burn preclinical model

Dramatic improvement in the mechanical properties of polydopamine/polyacrylamide hydrogel mediated human amniotic membrane

Femur bone marrow from brain death deceased donors as source of human mesenchymal stromal cells for cell therapy

Contact Info

Product

Resources

About